Oxabact[®] treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis
Stockholm – March 12, 2020. OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of a case report in Pediatric Nephrology. The report summarizes data from a 22-month course of treatment with Oxabact in a female infant with Primary Hyperoxaluria type 1 (PH1) and severe infantile oxalosis on dialysis. The treatment reduced plasma oxalate levels and stabilized systemic oxalosis.Infantile oxalosis, the most devastating form of primary hyperoxaluria type 1 (PH1), often leads to end-stage renal
The start list is full. People born in 1980 are particularly lucky.As always, the Ötztaler Cycle Marathon captivates a huge number of amateur cyclists. We received 17,000 registrations this year. The 238 km track with 5500 altitude meters across four Alpine passes between North and South Tyrol thrills the masses. On 30 August, four mountains, four great adventures - Kühtai, Brenner pass, Jaufen pass and Timmelsjoch which have become classics - are waiting for the 4000 starters.
Anniversary Bonus
The huge number of registrations for the 40th anniversary of the Ötztaler Cycle Marathon
